BPC-157 in 2026: The Evidence, the Rules, and Why Form Matters

What is BPC-157?

BPC-157 (short for Body Protection Compound 157) is a synthetic peptide composed of 15 amino acids, designed based on a sequence found in human gastric juice.

In the early 1990s, the Šikiric research group at the University of Zagreb isolated this peptide while studying gastric protective factors and first described its properties.

The initial observation was that something in the gastric juice protects the gastric mucosa from stomach acid, ethanol, and non-steroidal anti-inflammatory drugs. BPC-157 was identified as a stable and well-defined fragment of that protective system.

Unlike most peptides, BPC-157 is highly resistant to stomach acid, remaining structurally intact in human gastric juice for over 24 hours. This is why the peptide can be formulated for oral administration.

Mechanism of Action

Preclinical studies have shown that BPC-157 exerts its effects through several mechanisms:

• Angiogenesis: BPC-157 promotes the formation of new blood vessels, primarily through its interaction with VEGF (Vascular Endothelial Growth Factor) signaling. Since the formation of new blood vessels determines how fast tissues repair, this mechanism alone explains most of the peptide's downstream effects.
• Collagen synthesis and ligament repair: In animal models of ligament, tendon, and muscle injury, it enhances fibroblast activity and accelerates the structural remodeling phase of the healing process.
• Regulation of the inflammatory response: It can inhibit pro-inflammatory cytokine signaling without causing immunosuppression.
• Gut barrier function: It can restore tight junction function in models of intestinal injury, NSAID-induced damage, and inflammatory bowel disease.

These findings have been consistently confirmed in multiple animal models. But what about the evidence in humans?

Phase 2 Trial for Hamstring Injuries

As of 2026, the most significant development in the BPC-157 study is NCT07437547, a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating the efficacy of BPC-157 in acute grade II hamstring injury.

Acute hamstring injury is a well-defined orthopedic condition that already has established imaging biomarkers and well-defined functional recovery endpoints, and is very common among athletes, sometimes keeping them out of sports for months.

So it’s the type of injury where if BPC-157 is effective, it would show measurable effects in both structural healing (assessed with MRI) and functional recovery (time to resume activity, muscle strength tests, pain scores).

The design of this trial is also key. A phase 2 randomized controlled trial with appropriate blinding and placebo control provides the necessary evidence for the compound to move from “promising in animal studies” to “proven efficacy in humans.”

This is the first BPC-157 clinical trial with this design to enter the full investigation phase, and the results will serve as the basis for how this peptide will be addressed in the future across the board, from orthopedics, to sports medicine, and maybe even regulatory authorities.

Other recent human studies support this trend. A safety pilot study conducted in 2025 involving intravenous administration in healthy adults showed no adverse events at doses up to 20 mg.

Also, a Phase 2 trial of rotator cuff tendonitis conducted at the University of Zagreb in 2025 reported a 38% reduction in pain scores and a 29% improvement in range of motion. However, these results have not been peer-reviewed.

Regulatory Developments in 2026

In 2023, the FDA designated BPC-157 as a Class II controlled substance due to concerns regarding immunogenicity (immune reactions to peptide aggregates), the impurity profile in dispensing pharmacies, and a lack of human safety data. This Category II designation effectively prohibited pharmacies from formulating BPC-157.

In April 2026, BPC-157 was removed from Category II after the original nominators withdrew their nominations. The FDA's Pharmaceutical Formulation Advisory Board is scheduled to meet on July 23, 2026, to evaluate whether BPC-157 (particularly its acetate and free base forms) should be added to Category 1, the list of substances authorized for use in community pharmacies.

Something worthy of note is that the concerns regarding immunogenicity risks and impurity profiles were primarily related to injectable formulations prepared by community pharmacies.

In these cases, aggregated peptides or contaminants resulting from improper preparation methods can trigger immune reactions.

The underlying mechanisms of these issues do not necessarily apply in the same way as in oral formulations.

The Current Status of WADA

In January 2022, WADA added BPC-157 to its list of prohibited substances for Category S0 (Non-Approved Substances) and will add it to Category S2 in 2026. The prohibition is clear and stated below:

• In all cases, the use of BPC-157 was prohibited in all athletes who were tested for WADA doping, regardless of route of administration or whether it was used during competition.
• Oral, injectable and transdermal use is prohibited. Therapeutic use is also not allowed.
• The time of detection is a few weeks after use. The confirmed sentences to date are 2 to 4 years of ineligibility.

The use of BPC-157 in any form is prohibited by anyone subject to anti-doping testing by the USADA, NCAA, IOC, or WADA-affiliated organizations.

There is no gray area on this matter.

Why Dosage Form Is Important

For non-athletes, the more important question is “How does properly formulated oral BPC-157 differ from other products?”

Injectable BPC-157 supplied by research chemical suppliers still suffers from the problems the FDA initially tried to address when classifying it as Category 2: lack of quality control, lack of sterility assurance, variation in purity, and risk of immunogenicity. The removal of the Category 2 designation doesn’t change these underlying issues.

Properly formulated oral BPC-157 avoids the specific concerns of injectable formulations.

The fact that this peptide is naturally stable in gastric juice was demonstrated by the Sikiric group in 2011, but one of the major challenges lies in absorption, particularly in getting this difficult-to-digest peptide to actually cross the gut wall.

The latest oral formulation addresses this challenge through three layers. These include:

• An alginate salt form that enhances acid stability.
• Sodium bicarbonate buffer to optimize intestinal pH during the optimal absorption phase.
• To enhance absorption in the intestinal mucosa, intracellular transport enhancers such as sodium sulfate (SNAC) are used.

Properly formulated oral BPC-157 is a different product than the injectable form used as a research chemical. This distinction is crucial.

LVLUP’s BPC-ARG Double Strength and Wolverine are oral BPC-157 formulations centered on acid-stable alginate salts, pH buffers, and absorption enhancers, and are designed to address the “dosage form” challenge.

Sources

https://clinicaltrials.gov/study/NCT07437547

https://www.fda.gov/media/94155/download

https://pubmed.ncbi.nlm.nih.gov/21548867/

https://pubmed.ncbi.nlm.nih.gov/27847966/

https://pubmed.ncbi.nlm.nih.gov/38675421/

https://pubmed.ncbi.nlm.nih.gov/40131143/

https://www.wada-ama.org/en/prohibited-list

https://pubmed.ncbi.nlm.nih.gov/39204186/